Emerging markets have heated up for every industry, but the world's biggest pharmaceutical players have approached the challenges of capturing these promising markets in unique ways. Generic competition spawned by loose legal frameworks and a lack of solid middle-class wealth has hampered big pharma's push into some of the world's top developing economies, but the industry's top companies can't afford to miss out on this hundred-billion dollar opportunity in the making.
Sales around the pharmaceutical industry have been falling because of patent losses, and untapped emerging markets represent one last low-hanging frontier for the sector. Can big pharma take advantage of the world's fast-growing developing nations -- and are China, India, and other emerging economies even ready for the industry's entrance? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss below what you need to know about big pharma's battle to win the emerging markets.
Best China Companies To Buy Right Now: Design Studio Furniture Mfrltd (D11.SI)
Design Studio Furniture Manufacturer Ltd, together with its subsidiaries, engages in the manufacture, supply, and installation of paneling products primarily in Singapore, Malaysia, and the United Arab Emirates. It operates in three segments: Residential Property Projects, Hospitality and Commercial Projects, and Distribution Projects. The Residential Property Projects segment is involved in the manufacture, supply, and installation of paneling products, such as kitchen and vanity cabinets, wardrobes, doors and door frames, and furniture components. The Hospitality and Commercial Projects segment provides interior fitting-out services to hotels, resorts, office, shops, and bank branches. The Distribution Projects segment engages in the distribution of furniture products of various brands. The company offers its products and services under the in-house brand names of PANELZ, i.FORMZ, and GLITZ; and imported brand names of Siematic and Corian. The company was founded in 1994 and is headquartered in Singapore. Design Studio Furniture Manufacturer Ltd is a subsidiary of Depa Interiors LLC.
Best China Companies To Buy Right Now: Quintiles Transnational Holdings Inc (Q)
Quintiles Transnational Holdings Inc. is a provider of biopharmaceutical development services and commercial outsourcing services. The Company operates in two segments: Product Development and Integrated Healthcare Services. The Company�� Product Development segment operates as a contract research organization (CRO) focused primarily on Phase II-IV clinical trials and associated laboratory and analytical activities. The Company�� Integrated Healthcare Services segment is a global commercial pharmaceutical sales and service organizations and Integrated Healthcare Services provides a range of services, including commercial services, such as providing contract pharmaceutical sales forces in geographic markets, as well as healthcare business services for the healthcare sector, such as outcome-based and payer and provider services. In August 2012, it acquired Expression Analysis, Inc.
Product Development
Product Development provides services and that allow biopharmaceutical companies to outsource the clinical development process from first in man trials to post-launch monitoring. The Company�� service offering provides the support and functional necessary at each stage of development, as well as the systems and analytical capabilities. Product Development consists of clinical solutions and services and consulting. Clinical solutions and services provides services necessary to develop biopharmaceutical products, including project management and clinical monitoring functions for conducting multi-site trials (generally Phase II-IV) (core clinical) and clinical trial support services that improve clinical trial decision making and include global laboratories, data management, biostatistical, safety and pharmacovigilance, and early clinical development trials, and strategic planning and design services that improve decisions and performance. Consulting provides strategy and management consulting services based on life science and advanced analytics, as well as regulatory and comp! liance consulting services.
The Company competes with Covance, Inc., Pharmaceutical Product Development, Inc., PAREXEL International Corporation, ICON plc, inVentiv Health, Inc. (inVentive), INC Research and PRA International.
Integrated Healthcare Services
Integrated Healthcare Services provides the healthcare industry with both geographic presence and commercial capabilities. The Company�� commercialization services are designed to accelerate the commercial of biopharmaceutical and other health-related products. Service offerings include commercial services (sales representatives, strategy, marketing communications and other areas related to commercialization), outcome research (drug therapy analysis, real-world research and evidence-based medicine, including research studies to prove a drug�� value) and payer and provider services comparative and cost-effectiveness research capabilities, clinical management analytics, decision support services, medication adherence and health outcome optimization services, and Web-based systems for measuring quality improvement.
The Company competes with inVentiv, PDI, Inc., Publicis Selling Solutions, United Drug plc, EPS Corporation and CMIC HOLDINGS Co., Ltd.
Top Canadian Companies To Watch In Right Now: (NVDL)
NovaDel Pharma Inc., a specialty pharmaceutical company, develops oral spray formulations for marketed pharmaceuticals. The company?s proprietary technology enables delivery of drugs into the bloodstream leading to onset of action and patient benefits. Its oral spray candidates target angina, insomnia, erectile dysfunction, migraine headaches, and nausea. NovaDel Pharma?s marketed products include NitroMist for acute relief of an attack of angina pectoris, or acute prophylaxis of angina pectoris, due to coronary artery disease; and ZolpiMist for short-term treatment of insomnia. The company?s product candidates comprise Duromist, which is in preclinical development for erectile dysfunction; Zensana, which is in preclinical development for nausea; NVD-201, an oral spray formulation of sumatriptan in Phase 2/3 clinical trial to treat migraine headache; NVD-301, an oral spray formulation of midazolam in preclinical stage for the treatment of sedation during diagnostic, therap eutic, and endoscopic procedures; and ZolpiMist in Phase 1 clinical trial to treat middle of the night awakening. It has strategic license agreements with Talon Therapeutics, Inc., Kwang Dong Pharmaceuticals, and BioAlliance Pharma SA to develop and market Zensana; Manhattan Pharmaceuticals, Inc. for the company?s oral spray technology to deliver propofol for pre-procedural sedation; and Velcera Pharmaceuticals, Inc. for veterinary applications for marketed veterinary drugs. NovaDel Pharma also has agreements with Mist Acquisition, LLC, for the manufacturing and commercialization of the NitroMist lingual spray version of nitroglycerine; and ECR Pharmaceuticals Company, Inc. to manufacture and commercialize ZolpiMist. The company was formerly known as Flemington Pharmaceutical Corporation and changed its name to NovaDel Pharma Inc. in October 2002. NovaDel Pharma Inc. was founded in 1982 and is headquartered in Bridgewater, New Jersey.
Advisors' Opinion:- [By Stock Chaser]
Shares of Novadel Pharma Inc. (OTCBB:NVDL) are up 63% in midday trading at $0.08 with an intraday high of $0.11. NVDL has traded nearly 5 million shares so far today, well above its daily average of around 800 thousand shares. Novadel released their financials on April 2.
No comments:
Post a Comment